Applying Quality by Design (QbD) Concept for Fabrication of Chitosan Coated Nanoliposomes
Overview
Affiliations
In the present investigation, a quality by design (QbD) strategy was successfully applied to the fabrication of chitosan-coated nanoliposomes (CH-NLPs) encapsulating a hydrophilic drug. The effects of the processing variables on the particle size, encapsulation efficiency (%EE) and coating efficiency (%CE) of CH-NLPs (prepared using a modified ethanol injection method) were investigated. The concentrations of lipid, cholesterol, drug and chitosan; stirring speed, sonication time; organic:aqueous phase ratio; and temperature were identified as the key factors after risk analysis for conducting a screening design study. A separate study was designed to investigate the robustness of the predicted design space. The particle size, %EE and %CE of the optimized CH-NLPs were 111.3 nm, 33.4% and 35.2%, respectively. The observed responses were in accordance with the predicted response, which confirms the suitability and robustness of the design space for CH-NLP formulation. In conclusion, optimization of the selected key variables will help minimize the problems related to size, %EE and %CE that are generally encountered when scaling up processes for NLP formulations. The robustness of the design space will help minimize both intra-batch and inter-batch variations, which are quite common in the pharmaceutical industry.
Shreya A, Pandey A, Kulkarni S, Bhaskar K, Parekh H, Mutalik S Sci Rep. 2024; 14(1):28225.
PMID: 39548220 PMC: 11568265. DOI: 10.1038/s41598-024-79372-5.
Anjum V, Bagale U, Kadi A, Malinin A, Potoroko I, Alharbi A Molecules. 2024; 29(8).
PMID: 38675617 PMC: 11052499. DOI: 10.3390/molecules29081797.
Quality by Design Approach in Liposomal Formulations: Robust Product Development.
Alshaer W, Nsairat H, Lafi Z, Hourani O, Al-Kadash A, Esawi E Molecules. 2023; 28(1).
PMID: 36615205 PMC: 9822211. DOI: 10.3390/molecules28010010.
Toma I, Porfire A, Tefas L, Berindan-Neagoe I, Tomuta I Pharmaceutics. 2022; 14(7).
PMID: 35890377 PMC: 9322860. DOI: 10.3390/pharmaceutics14071482.
An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development.
Nemeth Z, Pallagi E, Dobo D, Kozma G, Konya Z, Csoka I Pharmaceutics. 2021; 13(7).
PMID: 34371762 PMC: 8309007. DOI: 10.3390/pharmaceutics13071071.